SecBot SecBot
25-NSE ·Filed May 22, 2026

NRXPW

NRX Pharmaceuticals, Inc.
BEARISH
Impact 8/10
Horizonimmediate Processed5mo ago SEC0001354457-26-000493
Notable filing: 25-NSE
Actionable Insight ▼ Bearish

Holders of NRXPW warrants should expect zero residual value post-delisting. Monitor for any final redemption payment from the company, but the filing indicates the securities are matured/retired. No further trading on Nasdaq.

DirectionBearish
Confidencehigh
Horizonimmediate

How the stock moved after the report

BEARISH VIEWSTOCK AT ENTRY AT T+5
Entry
$0.0142
T+0 close · May 22, 2026 · via day close
Latest settled
0.00%
T+5 · $0.0142
Vs SPY
−1.21%
α at T+5
Next horizon
T+20
due 5mo ago
  1. T+0 · May 26 $0.0142entry
  2. T+1 · 6mo ago 0.00%α −0.01% · $0.0142
  3. T+5 · 6mo ago 0.00%α −1.21% · $0.0142
  4. T+20 · due 5mo ago Pending
  5. T+60 · due 3mo ago Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Nasdaq filed a Form 25-NSE to remove from listing and deregister the warrants (NRXPW) of NRX Pharmaceuticals, Inc., effective May 22, 2026, under SEC Rule 12d2-2(a)(2) (matured, redeemed, or retired securities). This is a terminal event for the warrant security, eliminating any remaining trading value or conversion optionality.

Key Facts

  • Nasdaq filed Form 25-NSE to delist NRXPW warrants effective May 22, 2026.
  • Delisting is under Rule 12d2-2(a)(2) for matured, redeemed, or retired securities.
  • The warrant security will no longer trade on Nasdaq or be registered under the Exchange Act.
  • No financial terms or redemption price are disclosed in the filing.

Financial Impact

Warrant holders lose all trading liquidity and registration; the security is effectively extinguished. No redemption amount stated.

dilutionliquidity

Risk Factors

  • Complete loss of warrant value if no redemption proceeds are paid.
  • No further public market for the warrants; any residual claims must be pursued directly with the issuer.
  • Potential for related common stock (NRXP) to face continued operational or listing challenges.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
25-NSE Filing (Primary)0001354457-26-000493
Document: 0001354457-26-000493-index-headers.html0001354457-26-000493
Document: 0001354457-26-000493-index.html0001354457-26-000493
Document: 0001354457-26-000493.txt0001354457-26-000493

Track record

4 reports on NRXPW

Performance horizon
Filters
  1. Jun 4, 202623w ago 8-K Bearish 6/10 No price data
  2. Jun 3, 202623w ago 424B5 Bearish 6/10 No price data
  3. Jun 2, 202623w ago 424B5 Bearish 6/10 No price data
  4. May 22, 202625w ago 25-NSE Bearish 8/10 Viewing Entry $0.0142 to $0.0142 · 0.00% +1.21% vs SPY
Showing 4 of 4

US Market Status

Market Closed · Opens in 5h 59m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 22, 2026